Noumed Pharmaceuticals Pty Limited

Noumed Pharmaceuticals Pty Limited is an Australian private pharmaceutical company specializing in the development, manufacturing, and marketing of generic label pharmaceutical products. Established in August 2020, the company is headquartered in Adelaide, South Australia. Noumed Pharmaceuticals is committed to enhancing the quality of healthcare by providing a diverse range of high-quality, affordable medicines. The company is on a mission to manufacture onshore by 2026, with plans to invest $100 million in local manufacturing capabilities.

In addition to its manufacturing and marketing operations, Noumed Pharmaceuticals has developed a robust distribution network. In June 2025, the company relocated to a new, purpose-built, state-of-the-art manufacturing and warehouse facility located in the Nexus North Industrial Estate, Salisbury South, Adelaide. This 6,000 square meter, temperature-controlled warehouse has a 10,000-pallet capacity and is fully operational. The company is also in the final stages of planning a 20,000 square meter manufacturing facility to further support its onshore manufacturing goals.

Noumed Pharmaceuticals operates a comprehensive distribution network within Australia, centered around its advanced manufacturing and warehouse facility in Adelaide. The 6,000 square meter, temperature-controlled warehouse, with a 10,000-pallet capacity, serves as the primary hub for the company's logistics operations. This facility is strategically located to facilitate efficient distribution across the Australian market. The company is also in the process of establishing a 20,000 square meter manufacturing facility, which will further enhance its production and distribution capabilities.

Noumed Pharmaceuticals Pty Limited functions as a pharmaceutical manufacturer and distributor within Australia's supply chain. The company is actively involved in the production and marketing of generic pharmaceutical products, aiming to provide high-quality, affordable medicines to the Australian market. While the company imports certain pharmaceutical formulations, it is also focused on developing its own manufacturing capabilities to reduce reliance on imports and strengthen its position in the domestic market.

Noumed Pharmaceuticals has established relationships with several Indian pharmaceutical suppliers, with a significant portion of its imports originating from India. The company's total import value from India amounts to $4.2 million USD, encompassing 344 shipments across five therapeutic categories. The top five imported products include Fexofenadine ($2.8 million, 66.3% share), Clotrimazole ($643,000, 15.3% share), Docusate ($321,000, 7.6% share), Bisoprolol ($300,000, 7.1% share), and Bromhexine ($154,000, 3.7% share). The primary suppliers from India are LYRUS LIFE SCIENCES PRIVATE LIMITED ($2.5 million, 49.6% share) and CIPLA LIMITED ($1.2 million, 25.0% share). This indicates a high level of concentration in sourcing, with the top two suppliers accounting for 74.6% of the total import value.

The concentration in sourcing suggests that Noumed Pharmaceuticals may face risks associated with supplier dependency, such as potential disruptions in supply chains or price fluctuations. However, the company's strategic choice to import from established suppliers like LYRUS LIFE SCIENCES and CIPLA LIMITED may also reflect a focus on product quality and reliability. The stability of these relationships is crucial for maintaining a consistent supply of pharmaceutical products.

Noumed Pharmaceuticals' supply chain resilience is influenced by its sourcing strategy from Indian suppliers. The company's reliance on a limited number of suppliers, particularly LYRUS LIFE SCIENCES PRIVATE LIMITED and CIPLA LIMITED, may expose it to risks such as supply disruptions or geopolitical factors affecting trade between Australia and India. To mitigate these risks, Noumed Pharmaceuticals could consider diversifying its supplier base and establishing relationships with additional manufacturers. Additionally, increasing the diversity of imported formulations and exploring alternative shipping routes could enhance supply chain resilience. Ensuring that key suppliers comply with international Good Manufacturing Practice (GMP) standards is essential for maintaining product quality and regulatory compliance.

Noumed Pharmaceuticals' sourcing pattern, characterized by a high concentration of imports from a few Indian suppliers, has strategic implications for its competitive position in the Australian pharmaceutical market. While this approach may offer benefits such as streamlined logistics and established supplier relationships, it also exposes the company to risks associated with supplier dependency. To strengthen its competitive position, Noumed Pharmaceuticals could consider diversifying its supplier base, exploring alternative sourcing options, and enhancing its onshore manufacturing capabilities. For Indian exporters seeking to become alternative suppliers, understanding Noumed Pharmaceuticals' product portfolio and quality requirements is crucial. Demonstrating compliance with international GMP standards and the Therapeutic Goods Administration (TGA) regulations will be essential for establishing a successful partnership.

In Australia, the regulation of therapeutic goods, including pharmaceuticals, is overseen by the Therapeutic Goods Administration (TGA), a division of the Department of Health and Aged Care. The TGA is responsible for ensuring that therapeutic goods are safe, effective, and of high quality before they can be supplied in Australia. The primary legislation governing the regulation of therapeutic goods is the Therapeutic Goods Act 1989, which establishes a national system of controls relating to the quality, safety, efficacy, and timely availability of therapeutic goods used in Australia or exported from Australia. (tga.gov.au)

The Therapeutic Goods Regulations 1990 provide detailed requirements related to the manufacturing, supply, and advertising of therapeutic goods in Australia. These regulations set out important elements of the therapeutic goods regulatory scheme, including specifying fees for applying for marketing approval for a therapeutic good or for a manufacturing license, and setting out exemptions from the requirement for therapeutic goods other than medical devices to be included in the Australian Register of Therapeutic Goods (ARTG). (tga.gov.au)

To import therapeutic goods into Australia, companies must comply with the requirements set out by the TGA. Generally, therapeutic goods must be entered in the Australian Register of Therapeutic Goods (ARTG) before they can be lawfully imported into Australia, unless they are exempt from being entered in the ARTG. Every ARTG entry belongs to a 'sponsor' who is responsible for applying for and maintaining the ARTG entry. (tga.gov.au)

Importers must ensure that the therapeutic goods they import meet the TGA's standards for quality, safety, and efficacy. This includes ensuring that the goods are manufactured according to Good Manufacturing Practice (GMP) standards. The TGA recognizes GMP certificates from various international standards, including EU GMP, WHO GMP, and PIC/S. Importers must also hold a wholesale distribution authorization to supply therapeutic goods in Australia. (tga.gov.au)

Therapeutic goods imported into Australia must comply with the TGA's requirements for quality and labeling. This includes ensuring that the goods are manufactured according to GMP standards and that they meet the TGA's requirements for product and labeling standards. The TGA may specify Australian standards for particular types of therapeutic goods or for specific labeling, packaging, or other requirements. Importers must ensure that the goods they import meet these standards to ensure the safety and efficacy of the products supplied in Australia. (tga.gov.au)

As of March 2026, there have been no significant policy changes affecting Indian pharmaceutical imports into Australia. The regulatory framework governing the importation of therapeutic goods remains consistent, with the TGA continuing to enforce standards for quality, safety, and efficacy. Importers are advised to stay informed about any updates to the Therapeutic Goods Act 1989 and related regulations to ensure ongoing compliance.

Noumed Pharmaceuticals' product strategy focuses on importing and manufacturing generic pharmaceutical products across five therapeutic categories: Antihistamines & Allergy, Antifungals, Gastrointestinal, Cardiovascular, and Respiratory. The company's top five imported products include Fexofenadine (66.3% share), Clotrimazole (15.3% share), Docusate (7.6% share), Bisoprolol (7.1% share), and Bromhexine (3.7% share). This product mix indicates a strategic emphasis on addressing common health concerns such as allergies, fungal infections, gastrointestinal issues, cardiovascular conditions, and respiratory ailments. The market demand for these therapeutic areas is driven by the prevalence of these conditions in the Australian population and the need for accessible, cost-effective treatment options.

Noumed Pharmaceuticals' sourcing strategy involves importing finished pharmaceutical formulations from India, focusing on generic products that meet the company's quality standards. The company imports a diverse range of formulations, with a total of 292 unique formulations across five therapeutic categories. This approach allows Noumed Pharmaceuticals to offer